Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

<ul><li>On April 29, 2025, Abeona Therapeutics, Inc. (ABEO) announced that the U.S. Food and Drug Administration (FDA) has approved Zevaskyn (prademagene zamikeracel) for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB).</li><li>The company announced that the wholesale acquisition cost of Zevaskyn will be $3.1 million, which is significantly higher than what we had been modeling ($1.2 million).</li><li>Management also guided that following the commercial launch in the third quarter of 2025, the company expects 10-14 patients to be treated and revenue from those treatments to be recognized by the end of this year.</li></ul>

On April 29, 2025, Abeona Therapeutics, Inc. (ABEO) announced that the U.S. Food and Drug Administration (FDA) has approved Zevaskyn (prademagene zamikeracel) for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB).The company announced that the wholesale acquisition cost of Zevaskyn will be $3.1 million, which is significantly higher than what we had been modeling ($1.2 million).Management also guided that following the commercial launch in the third quarter of 2025, the company expects 10-14 patients to be treated and revenue from those treatments to be recognized by the end of this year.

ABEO: Zevaskyn  Approved by FDA  Raising Valuation to 11 